Sacubitril/valsartan exhibits CV and kidney protective benefits across the spectrum of kidney risk in heart failure patients: JACC Medha Baranwal7 May 2024 10:00 AM ISTUSA: A recent study sheds light on the efficacy and safety of sacubitril/valsartan, a novel therapy for heart failure, across varying degrees of renal...
Justify dose and rationality: CDSCO Panel Tells Dr. Reddy's Lab on Sacubitril-Valsartan tablets 25 mg Dr. Divya Colin6 May 2024 6:00 PM ISTNew Delhi: Noting that the proposed protocol is insufficient to prove the clinical relevance of the lower strength of Sacubitril/Valsartan...
Synokem gets CDSCO Panel Nod To Study FDC Dapagliflozin plus Sacubitril plus Valsartan Dr. Divya Colin10 March 2024 5:30 PM ISTNew Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Justify proposed dose and rationality: CDSCO Panel Tells Lupin on FDC Sacubitril plus Valsartan Dr. Divya Colin29 Jan 2024 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Lupin for the fixed-dose combination (FDC) cardiovascular drug Sacubitril plus...
Justify dose and rationality: CDSCO Panel Tells Alkem Laboratories on FDC Sacubitril plus Valsartan Dr. Divya Colin24 Dec 2023 5:30 PM ISTNew Delhi: In response to the proposal for bioequivalence (BE) study and Phase III clinical trial (CT) waiver for Sacubitril 12mg plus Valsartan 13mg...
Exemed Gets CDSCO Panel Nod To study dapagliflozin, Sacubitril, Valsartan as Sodium salt tablet Dr. Divya Colin29 Oct 2023 1:21 PM ISTNew Delhi: Exemed Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Submit dose Justification and international standards data: CDSCO panel Tells Synokem over Sacubitril, valsartan FDC Dr. Divya Colin27 Aug 2023 6:00 PM ISTNew Delhi: In response to the clinical trial protocol for the drug combination of sacubitril and valsartan presented by the drug maker Synokem, the...
Novartis to appeal to US Court of Appeals to uphold validity of Entresto combination patent Ruchika Sharma8 July 2023 3:00 PM ISTBasel: Novartis has announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent...
Sacubitril/valsartan beneficial in heart failure patients with ejection fraction above 40 percent Dr. Kamal Kant Kohli24 May 2023 11:30 AM ISTUSA: Treatment with Sacubitril/valsartan in patients with an ejection fraction (EF) above 40% results in a greater reduction in plasma NT-proBNP...
Novartis Entresto receives positive CHMP opinion for pediatric heart failure Ruchika Sharma2 April 2023 2:00 PM ISTPediatric heart failure represents an important cause of morbidity and mortality in childhood.
Interim relief to Novartis: Delhi HC reinstates Entresto (Sacubitril-Valsartan) patent in India Farhat Nasim27 Jan 2023 6:26 PM ISTDelhi: In an interim relief to Swiss pharma major Novartis, the Delhi High Court has reinstated Entresto (sacubitril/valsartan) patent in India amid...
Novartis in tight spot as HC stays grant of patent for Entresto amid generics fight Farhat Nasim13 Jan 2023 11:59 AM ISTNew Delhi: Amid the earlier patent of blockbuster heart failure drug Entresto expiring on January 16, 2023 concerns rise for the Swiss multinational...
